Article Data

  • Views 257
  • Dowloads 119

European Journal of Gynaecological Oncology (EJGO) is published by MRE Press from Volume 43 Issue 3 (2022). Previous articles were published by another publisher, and they are hosted by MRE Press on www.ejgo.net as a courtesy and upon agreement with European Journal of Gynaecological Oncology.

Original Research

Open Access

Effect of prechemotherapy filgrastim on the bone marrow toxicity of topotecan

  • H. Ozan1,*,
  • F. Ozkalemkas2
  • U. Ozan2
  • K. Ozerkan1
  • T. Bilgin1
  • F. KÜcÜiikyddiz3

1Uludag University Medical F acuity, Department of Obstetrics and Gynaecology, Turkey

2Uludag University Medical Faculty, Department of Haematology, Turkey

3Uludag University, Experimental Animals Research Laboratory, Bursa, Turkey

DOI: 10.12892/ejgo200106463 Vol.22,Issue 6,November 2001 pp.463-465

Published: 09 November 2001

*Corresponding Author(s): H. Ozan E-mail:

Abstract

Purpose: To investigate the efficacy and safety of single-dose filgrastim administered 24 hours prior to chemotherapy in the prevention of topotecan-related myeloid suppression.

Methods: No medication was given to 21 rats in group 1; 1.5 mg/m2/day topotecan was administered intraperitoneally for five days every three weeks to 21 rats in group II; a single dose of 5 microg/kg filgrastim was injected intraperitoneally 24 hours before the intraperitoneal administration of the same dose of topotecan to 21 rats in group III. After completion of six cycles of chemotherapy. the rats were decapitated and blood samples were immediately collected into citrated tubes for complete blood counts.

Results: White blood cell and lymphocyte counts in the control and the filgrastim + topotecan groups were similar (p > 0.05) and significantly higher than the counts in the topotecan group (p < 0.05). There was no difference in means of neutrophil, monocyte, eosinophil, basophil and erythrocyte counts among the groups (p > 0.05).

Conclusion: Filgrastim administration prior to chemotherapy seems to be beneficial and further investigations are needed.

Keywords

Filgrastim; Topotecan; Prechemotherapy; Myelosuppression

Cite and Share

H. Ozan, F. Ozkalemkas, U. Ozan, K. Ozerkan, T. Bilgin, F. Kücüiikyddiz. Effect of prechemotherapy filgrastim on the bone marrow toxicity of topotecan. European Journal of Gynaecological Oncology. 2001. 22(6);463-465.

References

[1] Creemers G. J., Bolis G., Gore M., Scarfone G., Lacave A. J., Guastalla J.P. et al.: "Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: results of a large European phase II study". J. Clin. Oneal., 1996, 14, 3056.

[2] ten Bokkel Huinink W.W., Gore M., Carmichael J., Gordon A., Malfetano J., Hudson I. et al.: "Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer". J. Clin. Oneal., 1997, 15, 2183.

[3] Frampton J. E., Lee C.R., Faulds D.;Filgrastim - A review of its pharmacological properties and therapeutic efficacy in neutropenia". Drugs, 1994, 48, 731.

[4] Serke S., Huhn D., Johnsen H. E., Herrmann R.: "Detrimental effects of prechemotherapy filgrastim". J. Clin. Oncol., 1999, 17. 1088.

[5] Welte K., Gabrilove J., Bronchud M. H.,P latzer E., Morstyn G: "Filgrastim (r-metHuG-CSF): The first IO years". Blood, 1996, 88, 1907.

[6] Lord B. I., Bronchud M. H., Owens S., Chang J., Howell A., Souza L. et al.: "The kinetics of human granulopoiesis following treatment with granulocyte colony-stimulating factor in vivo" Proc. Natl. Acad. Sci USA, 1989, 86, 9499.

[7] Bronchud M. H.,P otter M. R., Morgenstern G., Blasco M. J., Scarffe J. H., Thatcher N. et al.: "In vitro and in vivo analysis of the effects of recombinant human granulocyte colony-stimulating factor in patients". Br. J. Cancer,1988, 58, 64.

[8] Gabrilove J. L., Jakubowski A., Fain K., Grous J., Scher H., Sternberg C. et al.: "Phase I study of granulocyte colony-stimulating factor in patients with transitional cell carcinoma of the urothelium". J. Clin. Invest., 1988, 82, 1454.

[9] Ogawa M.: "Effects of hemopoietic growth factors on stem cells in vitro". Hematol. Oncol. Clin. North Am., 1989, 3, 453.

[10] Lyman G. H., Lyman C. G., Sanderson R. A., Balducci L.: "DeCIsion analysis of hematopoietic growth factor use in patients receiving cancer chemotherapy". J. Natl. Cancer Inst. USA, 1993, 85, 1251.

[11] Tjan-Heijnen V. C., Biesma B.. Festen J., Splinter T. A., Cox A., Wagener D. J. et al.: "Enhanced myelotoxicity due to granulocyte colony-stimulating factor administration until 48 hours before the next chemotherapy course in patients with small-cell lung carcinoma". J. Clin. Oncol., 1998, 16, 2708.

[12] Di Leo A., Bajetta E., Nole F., Biganzoli L., Ferrari L., Oriana S et al.: "The intramuscular administration of granulocyte colonystimulating factor as an adjunct to chemotherapy in pretreated ovarian cancer patients: an Italian Trials in Medical Oncology (ITMO) Group pilot study". Bl: J. Cancer. 1994, 69, 961.

[13] Martinez C.,U rbano-1s pizua A.,R ozman M.. Rovira M.,M arin P., Montfort N. et al.: "Effects of short-term administration of G-CSF (filgrastim) on bone marrow progenitor cells: analysis of serial marrow samples from normal donors". Bone Marrow Transplant, 1999, 23, 15.

[14] Demetri G.D., Griffin J. D.: "Granulocyte colony-stimulating factor and its receptor". Blood, 1991, 78, 2791.

[15] Gabrilove J. L.,J akubowski A.,S cher H.,S ternberg C.,Wong G., Grous J. et al.: "Effect of granulocyte colony-stimulating factor on neutropenia and associated morb汕ty due to chemotherapy for transitional-cell carcinoma of the urothelium". N. Engl. J. Med., 1988, 318, 1414.

[16] Watts M. J., Addison I., Long S. G., Hartley S., Warrington S., Boyce M. et al.: "Crossover study of the haematological effects and pharmacokinetics of glycosylated and non-glycosylated GCSF in healthy volunteers". Br. J. Haematol., 1997, 98, 474.

[17] Aglietta M., Montemurro F., Fagioli F., Volta C., Botto B., Cantonetti M. et al.: "Short term treatment with Escherichia coli recombinant human granulocyte-macrophage-colony stimulating factor prior to chemotherapy for Hodgkin disease": Cancer, 2000, 88, 454.

[18] de Wit R., Verweij J., Bontenbal M., Kruit W. H., Seynaeve C., Schmitz P. I. et al.: "Adverse effect on bone marrow protection of prechemotherapy granulocyte colony-stimulating factor support" J. Natl. Cancer Inst. USA, 1996, 88, 1393.

[19] Hasenburg A., Tong X. W., Rojas-Martinez A., Nyberg-Hoffman C.. Kie back C. C., Kaplan A. et al.: "Thymidine kinase gene therapy with concomitant topotecan chemotherapy for recurrent ovarian cancer". Cancer Gene Ther., 2000, 7, 839.

[20] Bishop M. R., Tarantolo S. R., Geller R. B., Lynch J. C., Bierman P. J.,P avletic Z. S. et al.: "A randomized,d ouble-blind trial of filgrastim (granulocyte colony-stimulating factor) versus placebo following allogeneic blood stem cell transplantation". Blood, 2000, 96, 80.

Current Issue

Vol.45, Issue 6, 14 December 2024

Table of contents
All Issues

Abstracted / indexed in

Science Citation Index Expanded (SciSearch) Created as SCI in 1964, Science Citation Index Expanded now indexes over 9,500 of the world’s most impactful journals across 178 scientific disciplines. More than 53 million records and 1.18 billion cited references date back from 1900 to present.

Biological Abstracts Easily discover critical journal coverage of the life sciences with Biological Abstracts, produced by the Web of Science Group, with topics ranging from botany to microbiology to pharmacology. Including BIOSIS indexing and MeSH terms, specialized indexing in Biological Abstracts helps you to discover more accurate, context-sensitive results.

Google Scholar Google Scholar is a freely accessible web search engine that indexes the full text or metadata of scholarly literature across an array of publishing formats and disciplines.

JournalSeek Genamics JournalSeek is the largest completely categorized database of freely available journal information available on the internet. The database presently contains 39226 titles. Journal information includes the description (aims and scope), journal abbreviation, journal homepage link, subject category and ISSN.

Current Contents - Clinical Medicine Current Contents - Clinical Medicine provides easy access to complete tables of contents, abstracts, bibliographic information and all other significant items in recently published issues from over 1,000 leading journals in clinical medicine.

BIOSIS Previews BIOSIS Previews is an English-language, bibliographic database service, with abstracts and citation indexing. It is part of Clarivate Analytics Web of Science suite. BIOSIS Previews indexes data from 1926 to the present.

Journal Citation Reports/Science Edition Journal Citation Reports/Science Edition aims to evaluate a journal’s value from multiple perspectives including the journal impact factor, descriptive data about a journal’s open access content as well as contributing authors, and provide readers a transparent and publisher-neutral data & statistics information about the journal.

Submission Turnaround Time

Conferences

Top